Search
01/09/2021
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
Vokinger, KN, Hwang, TJ, Daniore, P, Lee, CC, Tibau, A, Grischott, T, Rosemann, TJ, Kesselheim, AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9)DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33.012(Q1/1D).
01/09/2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6)DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3.637(Q2/5D).
01/08/2021
Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)
Jimenez-Labaig, P, Pacheco-Barcia, V, Cebria, A, Galvez, F, Obispo, B, Paez, D, Quilez, A, Quintanar, T, Ramchandani, A, Remon, J, Rogado, J, Sanchez, DA, Sanchez-Canovas, M, Sanz-Garcia, E, Sesma, A, Tarazona, N, Cotes, A, Gonzalez, E, Bosch-Barrera, J, Fernandez, A, Felip, E, Vera, R, Rodriguez-Lescure, A, Elez, E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4)DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6.883(Q1/3D).
01/08/2021
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Wilson, BE, Desnoyers, A, Nadler, MB, Tibau, A, Amir, E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16)DOI:10.1002/cam4.4029. PMID:34323019. IF:4.711(Q2/5D).
09/07/2021
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
Gil-Gil, MJ, Bellet, M, Bergamino, M, Morales, S, Barnadas, A, Manso, L, Saura, C, Fernandez-Ortega, A, Garcia-Martinez, E, Martinez-Janez, N, Mele, M, Villagrasa, P, Celiz, P, Martin, XP, Ciruelos, E, Pernas, S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 2021; 11DOI:10.3389/fonc.2021.645026. PMID:34307126. IF:5.738(Q2/4D).
01/07/2021
Lung cancer patients with COVID-19 in Spain: GRAVID study
Provencio, M, Gallego, JMM, Calles, A, Antonanzas, M, Pangua, C, Rubio, XM, Nadal, E, Castro, RL, Lopez-Martin, A, Del Barco, E, Domine, M, Franco, F, Diz, P, Sandoval, C, Girona, ES, Sullivan, I, Sala, MA, Ledo, GG, Cucurull, M, Mosquera, J, Martinez, M, Chara, LE, Arriola, E, Herrera, BE, Jarabo, JR, Alvarez, RA, Baena, J, Cao, MG. Lung cancer patients with COVID-19 in Spain: GRAVID study. LUNG CANCER. 2021; 157DOI:10.1016/j.lungcan.2021.05.014. PMID:34016490. IF:6.081(Q1/3D).